Poster 27
- Jun 8, 2023
- 1 min read
52 Week Safety and Efficacy of Amlitelimab in Participants With Moderate-to-Severe Atopic Dermatitis: Preliminary Analysis From the Open-Label Long-Term ATLANTIS Trial
Emma Guttman-Yassky, Nina Magnolo, Maxwell Sauder, Delphine Staumont, Ken Igawa, Mahreen Ameen, Lin Ma, Lindsay Ackerman, Guy Gherardi, Pei Li, Melanie Espinasse, Karl Yen, Charlotte Bernigaud


